CTLA4 and rheumatoid arthritis: Baseline RA disease activity was highest in the JAKi-treated group; the proportion of UIP pattern was highest in the CTLA4-Ig-treated group; and the proportion of concomitant treatment with MTX was highest in the TNFi-treated group.